Insights into Gazyva as a Treatment for Lupus/SLE

A recent article from Inside Precision Medicine states: For decades, systemic lupus erythematosus (SLE) has resisted tidy solutions, a shapeshifting autoimmune disease that crosses into different organ systems, flares without…

Continue Reading Insights into Gazyva as a Treatment for Lupus/SLE

AstraZeneca’s Tozorakimab Shows Promise as First-in-Class COPD Breakthrough

AstraZeneca has announced positive results from the pivotal phase III MIRANDA trial of tozorakimab, a groundbreaking first-in-class monoclonal antibody designed to treat Chronic Obstructive Pulmonary Disease (COPD). According to PharmaBiz.com,…

Continue Reading AstraZeneca’s Tozorakimab Shows Promise as First-in-Class COPD Breakthrough

“Not Defined By His Disability:” What Bennett Has Taught His Family About Spinal Muscular Atrophy

Editor's Note: Patient Worthy is honored to share this article from our friend Jessica Lynn. To see the article in its original format, please click here. When five-year-old Bennett hit…

Continue Reading “Not Defined By His Disability:” What Bennett Has Taught His Family About Spinal Muscular Atrophy

ModeX Advances Novel Tetraspecific Antibody Into First-in-Human Study for B‑Cell Lymphoma

As reported on PharmaBiz, ModeX Therapeutics, a clinical-stage biotechnology company within OPKO Health, has begun dosing patients in a first-in-human clinical trial evaluating MDX2003, a next-generation tetra-specific T‑cell engager for…

Continue Reading ModeX Advances Novel Tetraspecific Antibody Into First-in-Human Study for B‑Cell Lymphoma

Motif Neurotech Gains FDA Clearance to Launch First-in-Human Trial of Implantable BCI for Depression

As reported on Business Wire, Motif Neurotech has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its first clinical study evaluating an implantable brain–computer interface (BCI)…

Continue Reading Motif Neurotech Gains FDA Clearance to Launch First-in-Human Trial of Implantable BCI for Depression

Breakthrough in Pancreatic Cancer Treatment: How Revolution Medicines’ RAS Inhibitor Is Reshaping Patient Outcomes

Pancreatic cancer remains one of medicine's most formidable challenges, and recent clinical developments suggest a potential turning point. Revolution Medicines presented compelling evidence this week that its experimental drug daraxonrasib…

Continue Reading Breakthrough in Pancreatic Cancer Treatment: How Revolution Medicines’ RAS Inhibitor Is Reshaping Patient Outcomes